{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:34:13Z","timestamp":1787243653625,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7202150"],"award-info":[{"award-number":["7202150"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences & Peking Union Medical College","doi-asserted-by":"publisher","award":["2016-I2M-2\u2013001"],"award-info":[{"award-number":["2016-I2M-2\u2013001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008235","name":"Peking Union Medical College Hospital","doi-asserted-by":"publisher","award":["2019ZLH101"],"award-info":[{"award-number":["2019ZLH101"]}],"id":[{"id":"10.13039\/501100008235","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.phrs.2021.105931","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T20:53:42Z","timestamp":1633640022000},"page":"105931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-4705","authenticated-orcid":false,"given":"Binghao","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2881-1601","authenticated-orcid":false,"given":"Yan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuekun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congxin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7818","key":"10.1016\/j.phrs.2021.105931_bib1","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41586-020-2481-8","article-title":"The national lung matrix trial of personalized therapy in lung cancer","volume":"583","author":"Middleton","year":"2020","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.phrs.2021.105931_bib2","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N. Engl. J. Med"},{"issue":"10089","key":"10.1016\/j.phrs.2021.105931_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.phrs.2021.105931_bib4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S1470-2045(17)30339-X","article-title":"Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"10072","key":"10.1016\/j.phrs.2021.105931_bib5","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2021.105931_bib6","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann. Oncol."},{"issue":"22","key":"10.1016\/j.phrs.2021.105931_bib7","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer","volume":"36","author":"Solomon","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2021.105931_bib8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in East Asian patients with ALK-positive advanced non-small cell lung cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105931_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir. Med"},{"issue":"31","key":"10.1016\/j.phrs.2021.105931_bib10","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1200\/JCO.20.00505","article-title":"Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial","volume":"38","author":"Camidge","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2021.105931_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"issue":"21","key":"10.1016\/j.phrs.2021.105931_bib12","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2021.105931_bib13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2021.105931_bib14","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.jtho.2020.08.003","article-title":"ID:1882 phase III randomized study of ensartinib vs crizotinib in anaplastic lymphoma kinase (ALK) POSITIVE NSCLC patients: eXalt3","volume":"15","author":"Selvaggi","year":"2020","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2021.105931_bib15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"21","key":"10.1016\/j.phrs.2021.105931_bib16","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.phrs.2021.105931_bib17","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"80","key":"10.1016\/j.phrs.2021.105931_bib18","doi-asserted-by":"crossref","first-page":"35181","DOI":"10.18632\/oncotarget.26073","article-title":"Brain metastases in ALK-positive NSCLC - time to adjust current treatment algorithms","volume":"9","author":"Griesinger","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.phrs.2021.105931_bib19","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s10147-014-0760-9","article-title":"Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations","volume":"20","author":"Iuchi","year":"2015","journal-title":"Int J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.phrs.2021.105931_bib20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.ejca.2014.02.001","article-title":"Prospective screening for ALK: clinical features and outcome according to ALK status","volume":"50","author":"Fallet","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2021.105931_bib21","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.3747\/co.25.3733","article-title":"Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?","volume":"25","author":"Abdallah","year":"2018","journal-title":"Curr. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105931_bib22","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1158\/2159-8290.CD-13-0846","article-title":"The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer","volume":"4","author":"Friboulet","year":"2014","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.phrs.2021.105931_bib23","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00280-014-2578-6","article-title":"Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases","volume":"74","author":"Kodama","year":"2014","journal-title":"Cancer Chemother. Pharm."},{"issue":"22","key":"10.1016\/j.phrs.2021.105931_bib24","doi-asserted-by":"crossref","first-page":"5686","DOI":"10.1158\/1078-0432.CCR-14-1511","article-title":"Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib","volume":"20","author":"Katayama","year":"2014","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.phrs.2021.105931_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jtho.2015.10.010","article-title":"Alectinib dose escalation reinduces central nervous system responses in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer relapsing on standard dose alectinib","volume":"11","author":"Gainor","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2021.105931_bib26","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern Med"},{"key":"10.1016\/j.phrs.2021.105931_bib27","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2021.105931_bib28","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"7521","key":"10.1016\/j.phrs.2021.105931_bib29","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.phrs.2021.105931_bib30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/0962280211432219","article-title":"A practical introduction to multivariate meta-analysis","volume":"22","author":"Mavridis","year":"2013","journal-title":"Statl. Methods Med Res"},{"issue":"20","key":"10.1016\/j.phrs.2021.105931_bib31","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat. Med"},{"issue":"7414","key":"10.1016\/j.phrs.2021.105931_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.phrs.2021.105931_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J. Clin. Epidemiol."},{"issue":"23","key":"10.1016\/j.phrs.2021.105931_bib34","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N. Engl. J. Med"},{"issue":"4","key":"10.1016\/j.phrs.2021.105931_bib35","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.jtho.2020.12.022","article-title":"Lorlatinib should not be considered as the preferred first-line option in patients with advanced ALK rearranged NSCLC","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105931_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030526","article-title":"Efficacy of crizotinib, ceritinib, and alectinib in ALK-positive non-small cell lung cancer treatment: a meta-analysis of clinical trials","volume":"12","author":"Hoang","year":"2020","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.phrs.2021.105931_bib37","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1002\/cam4.1768","article-title":"The efficacy and safety of ALK inhibitors in the treatment of ALK-positive non-small cell lung cancer: a network meta-analysis","volume":"7","author":"Fan","year":"2018","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.phrs.2021.105931_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/medicina55020029","article-title":"Which should be used first for ALK-positive non-small-cell lung cancer: chemotherapy or targeted therapy? A meta-analysis of five randomized trials","volume":"55","author":"Lee","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.phrs.2021.105931_bib39","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2020.04.011","article-title":"Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: a systematic review and meta-analysis","volume":"144","author":"Breadner","year":"2020","journal-title":"Lung Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2021.105931_bib40","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.21037\/jtd.2019.03.76","article-title":"Anaplastic lymphoma kinase inhibitors in non-small cell lung cancer patients with brain metastases: a meta-analysis","volume":"11","author":"Zhang","year":"2019","journal-title":"J. Thorac. Dis."},{"issue":"2","key":"10.1016\/j.phrs.2021.105931_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229179","article-title":"ALK inhibitors for non-small cell lung cancer: a systematic review and network meta-analysis","volume":"15","author":"Elliott","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2021.105931_bib42","first-page":"4","article-title":"Brigatinib and alectinib for ALK rearrangement-positive advanced non-small cell lung cancer with or without central nervous system metastasis: a systematic review and network meta-analysis","volume":"12","author":"Ando","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.phrs.2021.105931_bib43","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.21037\/apm-19-643","article-title":"Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis","volume":"9","author":"Yang","year":"2020","journal-title":"Ann. Palliat. Med."},{"issue":"12","key":"10.1016\/j.phrs.2021.105931_bib44","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(17)30680-0","article-title":"Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial","volume":"18","author":"Shaw","year":"2017","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2021.105931_bib45","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1021\/jm500261q","volume":"57","author":"Johnson","year":"2014","journal-title":"J. Med Chem."},{"issue":"1","key":"10.1016\/j.phrs.2021.105931_bib46","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2015.05.010","article-title":"PF-06463922, an ALK\/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models","volume":"28","author":"Zou","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2021.105931_bib47","doi-asserted-by":"crossref","DOI":"10.17305\/bjbms.2020.5066","article-title":"Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis","author":"Feng","year":"2020","journal-title":"Bosn. J. Basic Med Sci."},{"issue":"10","key":"10.1016\/j.phrs.2021.105931_bib48","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2021.105931_bib49","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2019.01.019","article-title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance","volume":"41","author":"Okada","year":"2019","journal-title":"EBioMedicine"},{"issue":"11","key":"10.1016\/j.phrs.2021.105931_bib50","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41571-018-0081-4","article-title":"Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?","volume":"15","author":"Recondo","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005156?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821005156?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:43:56Z","timestamp":1762353836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821005156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":50,"alternative-id":["S1043661821005156"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105931","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105931"}}